This article is more than 5 years old. Information may no longer be current.
VIDEO: Lichtenstein discusses importance of precision medicine in IBD
Click Here to Manage Email Alerts
ORLANDO — In this video exclusive from AIBD 2016, Gary R. Lichtenstein, MD, professor of medicine and director of the Inflammatory Bowel Disease center at University of Pennsylvania in Philadelphia, discusses the importance of a precision medicine approach when treating patients with IBD.
“Dr. Hanauer recently presented information that focused on [how] insurers have really been the individuals that have enabled us to use particular agents at various phases of disease, and that’s fine if one size fits all and we do what’s called the ‘step-up’ approach, but the reality is we recognize a step-up approach is not the best approach,” he said. “We don’t start with the least toxic agents as the disease progresses, we try to initiate the appropriate therapy for the appropriate individual based on the prognosis they have and [their] severity of disease.”
Reference:
Lichtenstein GR. “Emerging Therapies for IBD.” Presented at: Advances in Inflammatory Bowel Diseases; Dec. 8-10, 2016; Orlando, Fla.
Disclosures: Lichtenstein reports financial relationships with AbbVie, Actavis, Alaven Corporation, Ferring, Hospira, Janssen Ortho Biotech, Luitpold/American Reagent, Pfizer, Prometheus Laboratories, Salix Pharmaceuticals, Santarus, Shire, Takeda and UCB.